<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Travere-Therapeutics-Inc-US89422G1076">Travere Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-expands-approval-travere-therapeutics-drug-rare-kidney-disease-2026-04-13/">US FDA expands approval for Travere Therapeutics&#39; drug for rare kidney disease</a>
    </div>

      <div class="me-0 me-md-5">
        The U.S. Food and ​Drug Administration has approved the expanded ‌use of Travere Therapeutics&#39; drug to treat a rare kidney disorder, the company said ​on Monday.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Travere-Therapeutics-Inc-US89422G1076">Travere Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260413839195/en/Travere-Therapeutics-Announces-Full-FDA-Approval-of-FILSPARI%C2%AE-sparsentan-the-First-and-Only-Approved-Medicine-for-FSGS/">Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS</a>
    </div>

      <div class="me-0 me-md-5">
        SAN DIEGO--(BUSINESS WIRE)---- $TVTX--U.S. FDA approves FILSPARI (sparsentan) for FSGS.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Travere-Therapeutics-Inc-US89422G1076/load_more?page=5">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>